January 8, 2018 / 1:24 PM / 13 days ago

BRIEF-Revance Therapeutics Inc Announced Interim 8-Week Phase 2A Results For Rt002 In Treating Plantar Fasciitis

Jan 8 (Reuters) - Revance Therapeutics Inc:

* REVANCE THERAPEUTICS INC - ANNOUNCED INTERIM 8-WEEK PHASE 2A RESULTS FOR RT002 IN TREATING PLANTAR FASCIITIS

* REVANCE THERAPEUTICS INC - TRIAL‘S PRIMARY ENDPOINT SHOWED ROBUST IMPACT ON PAIN, WITH GREATER THAN 50% REDUCTION FOR PATIENTS TREATED WITH RT002

* REVANCE THERAPEUTICS INC - RT002 APPEARED TO BE GENERALLY SAFE AND WELL-TOLERATED THROUGH WEEK 8

* REVANCE THERAPEUTICS - EXPECT TO CONDUCT ANOTHER PHASE 2A TRIAL WITH MODIFIED DESIGN TO DEMONSTRATE RT002‘S ABILITY TO TREAT PLANTAR FASCIITIS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below